Sort   by:  
 Page size 
UnknownA T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.
Not available
S-EPMC10562195 | biostudies-literature
UnknownOncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Not available
S-EPMC9670134 | biostudies-literature
UnknownSingle-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection.
Not available
S-EPMC8527104 | biostudies-literature
UnknownSARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition.
Not available
S-EPMC7921772 | biostudies-literature
UnknownProgress and prospects on vaccine development against monkeypox infection.
Not available
S-EPMC10186953 | biostudies-literature
UnknownEngineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy.
Not available
S-EPMC10224353 | biostudies-literature
UnknownImplications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.
Not available
S-EPMC7557813 | biostudies-literature
UnknownCharacterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Not available
S-EPMC7956771 | biostudies-literature
UnknownNanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
Not available
S-EPMC7872859 | biostudies-literature
UnknownCRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX.
Not available
S-EPMC9880309 | biostudies-literature
Sort   by:  
 Page size